Treatment of acute myelogenous leukaemia in patients aged 50-65: idarubicin is more effective than zorubicin for remission induction and prolonged disease-free survival can be obtained using a unique consolidation course.

Autor:	Pignon, B., Witz, F., Desablens, B., Leprise, P. Y., Francois, S., Linassier, C., Berthou, C., Caillot, D., Lioure, B., Cahn, J. Y., Casassus, P., Sadoun, A., Audhuy, B., Guyotat, D., Briere, J., Vilque, J. P., Baranger, L., Polin, V., Berthaud, P., Hurteloup, P.
Zdroj:	British Journal of Haematology; Aug1996, Vol. 94 Issue 2, p333-341, 9p
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Plný text